Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04354428 · ClinicalTrials.gov registry record · Phase 2
Treatment for COVID-19 in High-Risk Adult Outpatients
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 289
- Enrollment target
NCT04354428: Clinical Trial Phase 2 study, sponsored by University of Washington.
NCT04354428 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 289 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (117% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04354428, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 289 participants
- Enrollment target
Study Summary
This is a randomized trial for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in high-risk adults not requiring hospital admission.The overarching goal of this study is to assess the effectiveness of interventions on the incidence of lower respiratory tract infection (LRTI) progression among high-risk adult outpatients with SARS-CoV-2 infection to inform public health control strategies.
Primary Outcome
Resting blood oxygen saturation (SpO2\<93%) level sustained for 2 readings 2 hours apart and presence of subjective dyspnea or cough
Interventions
- DRUG Azithromycin
- DRUG Ascorbic Acid
- DRUG Folic Acid
- DRUG Hydroxychloroquine Sulfate
- DRUG Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 289 participants |
| Start Date | 2020-04-16 |
| Est. Completion | 2020-11-30 |
| Phase | Phase 2 |
Why NCT04354428 stopped before completion
NCT04354428 is an interventional study that assigns participants to a tested intervention. The registered 289 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (117% higher).
The record links to 0 conditions, and to 5 interventions - of which Azithromycin is the first listed.
NCT04354428 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04354428 about?
NCT04354428 is a clinical study titled "Treatment for COVID-19 in High-Risk Adult Outpatients". This is a randomized trial for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in high-risk adults not requiring hospital admission.The overarching goal of this study is to assess the effectiveness of interventions on the incidence of lower respiratory tract i...
What is the current status of trial NCT04354428?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 289 participants. The study started on 2020-04-16. Estimated completion is 2020-11-30.
What interventions are being tested in trial NCT04354428?
The interventions under investigation include: Azithromycin (DRUG), Ascorbic Acid (DRUG), Folic Acid (DRUG), Hydroxychloroquine Sulfate (DRUG), Lopinavir 200 MG / Ritonavir 50 MG [Kaletra] (DRUG).
Who is sponsoring clinical trial NCT04354428?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04354428's enrollment target sits among peer trials
289 191st of 2000 higher than 1,810 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06465199 · 289 participants · Phase 1
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI